

Applicants: Carlos Cordon-Cardo et al.  
Serial No.: 10/009,861  
Filed: December 10, 2001  
Page 2

In the claims:

Please replace the claims with the listing of claims below.

1. - 18. (cancelled)

19. (currently amended) A method for treating a subject afflicted with androgen-independent prostate cancer, wherein the prostate cancer is characterized by ~~prostate cancer cells which overexpress~~ overexpression of Her-2/neu protein, which method comprises administering to the subject (i) a therapeutically effective amount of a ~~humanized monoclonal antibody which selectively binds to an extracellular domain of the Her-2/neu protein~~ HERCEPTIN in conjunction with (ii) a therapeutically effective amount of an ~~antitumor chemotherapeutic agent~~ paclitaxel, wherein treatment with ~~the monoclonal antibody~~ HERCEPTIN and ~~the chemotherapeutic agent~~ paclitaxel inhibits prostate cancer [[cell]] growth more than treatment with either ~~the monoclonal antibody~~ HERCEPTIN alone or ~~the chemotherapeutic agent~~ paclitaxel alone, so as to thereby treat the subject afflicted with androgen-independent prostate cancer.

20. - 30. (cancelled)